null - FindTrial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2012-000770-36-FR

Enrollment

Registered

2012-08-14

Start date

2013-05-14

Completion date

Unknown

Last updated

2018-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: GLIVEC 100 mg Product Name: Imatinib mésilate Pharmaceutical Form: Tablet Trade Name: TASIGNA 200mg Product Name: NILOTINIB Pharmaceutical Form: Capsule

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Belgium, France

Contacts

Public ContactDOROTHEE SALEMBIER

CENTRE HOPITALIER REGIONAL ET UNIVERSITAIRE

frc@chru-lille.fr0033320444145

Outcome results